Van Den Berg Management I Trimmed Its Interactive Brokers Group In (IBKR) Position; Novabay Pharmaceuticals (NYSEAMERICAN:NBY) Sellers Decreased By 2.63% Their Shorts

April 18, 2018 - By Linda Rogers

Interactive Brokers Group, Inc. (NASDAQ:IBKR) Logo

Novabay Pharmaceuticals Inc (NYSEAMERICAN:NBY) had a decrease of 2.63% in short interest. NBY’s SI was 148,000 shares in April as released by FINRA. Its down 2.63% from 152,000 shares previously. With 8,600 avg volume, 17 days are for Novabay Pharmaceuticals Inc (NYSEAMERICAN:NBY)’s short sellers to cover NBY’s short positions. The SI to Novabay Pharmaceuticals Inc’s float is 2.88%. It closed at $3.25 lastly. It is down 12.00% since April 18, 2017 and is downtrending. It has underperformed by 23.55% the S&P500.

Van Den Berg Management I Inc decreased Interactive Brokers Group In (IBKR) stake by 50.86% reported in 2017Q4 SEC filing. Van Den Berg Management I Inc sold 51,920 shares as Interactive Brokers Group In (IBKR)’s stock rose 10.58%. The Van Den Berg Management I Inc holds 50,170 shares with $2.97 million value, down from 102,090 last quarter. Interactive Brokers Group In now has $29.98 billion valuation. The stock decreased 2.14% or $1.59 during the last trading session, reaching $72.81. About 955,733 shares traded or 33.72% up from the average. Interactive Brokers Group, Inc. (NASDAQ:IBKR) has risen 93.22% since April 18, 2017 and is uptrending. It has outperformed by 81.67% the S&P500.

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, makes, and markets anti-infective products for the eye care market in the United States. The company has market cap of $55.54 million. The Company’s commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. It currently has negative earnings. The firm has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets.

Since October 17, 2017, it had 0 insider purchases, and 10 selling transactions for $8.95 million activity. Brody Paul Jonathan sold $550,049 worth of stock or 11,311 shares. Mendonca Denis also sold $57,222 worth of Interactive Brokers Group, Inc. (NASDAQ:IBKR) shares. Nemser Earl H also sold $1,048 worth of Interactive Brokers Group, Inc. (NASDAQ:IBKR) on Thursday, October 26. $1.53 million worth of Interactive Brokers Group, Inc. (NASDAQ:IBKR) shares were sold by Frank Thomas AJ.

Interactive Brokers Group, Inc. (NASDAQ:IBKR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>